Sangamo Therapeutics, Inc. (NASDAQ:SGMO) is one of the stocks under $1 that will explode.
Sangamo Therapeutics, Inc.’s share price has underperformed over the past year, down nearly 64%. However, by the time the market opened on January 9, 2026, the stock had recorded a 7.19% share price gain over the previous five sessions.
This recent stabilization in the stock is somewhat supported by a recent key pipeline update that refocused investor attention on the company’s lead gene therapy program.
On December 18, 2025, Sangamo Therapeutics, Inc. announced the initiation of a rolling Biologics License Application (BLA) submission to the U.S. Food and Drug Administration. The company is seeking accelerated approval of isaralgagene civaparvovec (ST-920) for adults with Fabry disease, with the submission allowing completed modules to be reviewed on an ongoing basis. It will potentially shorten the regulatory timeline ahead of a full filing expected in Q2 2026.
The data from the registration STAAR study support the BLA, as it demonstrated ST-920’s potential as a one-time, durable gene therapy. Importantly, the FDA validated the claim that the mean annualized eGFR slope at 52 weeks can serve as the accelerated approval endpoint, as dosed patients showed a positive slope indicative of kidney function stabilization. The regulatory momentum is soaring high, with ST-920 also carrying Orphan Drug, Fast Track, and RMAT designations.
Sangamo Therapeutics, Inc., a clinical-stage biotech company, develops genomic medicines across inherited metabolic, neurologic, and immune diseases. The company leverages gene therapy and genome engineering platforms to pursue durable, potentially curative treatments.
READ NEXT: 7 Best Rising Tech Stocks to Buy Now and 12 Best Multibagger Stocks to Buy Heading into 2026.
